Today, I’d like to look at how well public cell therapy and stem cell companies were doing on the market in 2011. By analyzing data, available for public, we can learn about trust and investor confidence in the sector. We can track stock market charts and quarterly earnings reports.
First, I’d like to look at stock market charts. I’ve picked the most interesting companies (n=22) to watch and embedded charts from Dec. 31, 2010 to Dec. 30, 2011 time period. You can also look at % of growth or loss in one year period.
Geron (GERN) down 71.48%
Flash Player 9 or higher is required to view the chart Click here to download Flash Player nowAdvanced Cell Technology (OTC:ACTC) down 60.57%
Neostem (NBS)
Neuralstem (CUR) down 54.71%
Mesoblast (ASX:MSB) up 55.87%
Reneuron (LON:RENE) down 31.47%
Dendreon (DNDN) down 78.23%
Athersys (ATHX) down 29.95%
Bioheart (OTC:BHRT) down 86.39%
Biotime (BTX) down 30.25%
More:
Pluristem (PSTI) up 53.09%
Aastrom (ASTM) down 19.47%
Cord Blood America (OTC:CBAI) down 95.71%
StemCells (STEM) down 23.88%
ImmunoCellular Therapeutics (OTC:IMUC) down 0.74%
MediStem (PINK:MEDS) up 3.7% (0.01)
Tengion (TNGN) down 81%
Tigenix (EBR:TIG) down 42.97%
Cellectis (EPA:ALCLS) down 1.69% (0.11)
China Cord Blood (CO) down 37.56%
Cytori Therapeutics (CYTX) down 60.55%
CRYO-CELL International (OTC:CCEL) down 7.55%
Earnings report card, which was tracked on Scimitar Equity Blog:
Q1/2011 (all companies – net loss, except Osiris)
Q2/2011 (all companies – net loss!)
Q3/2011 (all companies – net loss, except Osiris).
Q4/2011 – upcoming!
Conclusions:
- From 22 analyzed companies only 2 (Mesoblast and Pluristem) gain some profit on stock market during 2011. Most companies lost money and few remained flat.
- There was no interest from investors to cell therapy/ stem cell companies. Public and investors didn’t trust this sector in 2011.
- Despite the high volatility in the sector, I didn’t notice sensitivity of investors to positive press-releases. For example, despite announcements of remarkable clinical trials by Advanced Cell Technology, Neuralstem and Reneuron, it didn’t shake their stock prices significantly. The same thing we can observe in cellular immunotherapy. For example, despite positive results of clinical trials, announced by ImmunoCellular Therapeutics, investors did not react.
- Cell therapy sector was undervalued by investors in 2011
What do you think about public cell therapy companies performance on a market in 2011?
PS: For e-mail and RSS readers: There are interactive charts embedded in the post. Please visit a blog to view it. In order to view charts you should have Adobe Flash Player 9 or higher.
***********************
RegenMed Digest on Stem Cell Assays is sponsored by Regenerative Medicine Jobs. Please visit Regenerative Medicine Jobs for recent position openings.
Related posts:
- Regenerative medicine and cell therapy industry in 2011
- New edition of international standards for cellular therapy products open for public comments
- Cell therapy industry – market size and more predictions
- Cell therapy and RegenMed industry in financial 2010 and projections for the future
- Is FDA slowing down the progress in clinical cell therapy?
{ 3 comments… read them below or add one }
Great article. What do you think is the reason for no or less profit by stem cell companies and low interest by investors, despite the promising therapeutic application stem cells offer.
Thank you Richa!
I think the reason is a fear of “no quick return”. Investment in this sector has been risky for the last few years -
http://stemcellassays.com/2011/09/regenerative-medicine-industry-worthwhile-investment/
Yet another trend – loss of trust to all biotech on early stages of development. VC’s want to see extremely good polished product on phases 2-3 of trials, but not invest in pre-clinical mouse work, validation or phase 1. Because failure rate is high and product are not as good as we want them to be. Cell products are extremely hard to tune and standardize.
Also in cell therapy industry we don’t have yet many examples (proofs) of how well products could be sold on the market. The industry is young and evolving right now, so we need “show cases” in order to attract investors. This is a difference with biotech and pharma.
The reason for no or less profit by stem cell companies is just the lack of sales. Promising therapeutic application stem cells offer for when? There is still a long way to get prescribed a stem cells therapy.
It`s quite possible that investors realize that investments in stem cells companies are long term investments, may be even longer. They are waiting to seeing the regulatory systems` behaviour, and the big pharmas` behaviour. How many stem cells therapies have been approved in 2011? How many stem cells company have been bought by a Pharma Company in 2011?